Does RUCAPARIB CAMSYLATE Cause Tumour marker increased? 257 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 257 reports of Tumour marker increased have been filed in association with RUCAPARIB CAMSYLATE (Rubraca). This represents 3.1% of all adverse event reports for RUCAPARIB CAMSYLATE.
257
Reports of Tumour marker increased with RUCAPARIB CAMSYLATE
3.1%
of all RUCAPARIB CAMSYLATE reports
7
Deaths
32
Hospitalizations
How Dangerous Is Tumour marker increased From RUCAPARIB CAMSYLATE?
Of the 257 reports, 7 (2.7%) resulted in death, 32 (12.5%) required hospitalization.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUCAPARIB CAMSYLATE. However, 257 reports have been filed with the FAERS database.
What Other Side Effects Does RUCAPARIB CAMSYLATE Cause?
Fatigue (2,494)
Nausea (2,219)
Malignant neoplasm progression (1,162)
Decreased appetite (787)
Constipation (763)
Diarrhoea (759)
Vomiting (759)
Asthenia (660)
Adverse event (571)
Carbohydrate antigen 125 increased (562)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
ANASTROZOLE (142)
Which RUCAPARIB CAMSYLATE Alternatives Have Lower Tumour marker increased Risk?
RUCAPARIB CAMSYLATE vs RUFINAMIDE
RUCAPARIB CAMSYLATE vs RUPATADINE
RUCAPARIB CAMSYLATE vs RUXOLITINIB
RUCAPARIB CAMSYLATE vs SABRIL
RUCAPARIB CAMSYLATE vs SACCHAROMYCES CEREVISIAE